Enclomiphene

  1. New Member
    Random987's Avatar
    Join Date
    Jul 2005
    Age
    45
    Posts
    81
    Rep Power
    161
    Level
    8
    Lv. Percent
    48.39%

    Enclomiphene


    With all the talk about SARMS as being the wave of the future for TRT, it appears they are still looking at other options...


    Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men.
    Hill S, Arutchelvam V, Quinton R.

    Department of Clinical Pharmacology & Therapeutics, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.

    Enclomiphene (Androxal), in development by Repros Therapeutics Inc, is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes. Enclomiphene constitutes the trans-stereoisomer of clomiphene citrate, a drug that has been widely prescribed for several decades for the treatment of female ovulatory dysfunction. Because of the antagonistic effects of enclomiphene, the drug has the potential to increase serum testosterone levels in men with secondary hypogonadism by restoring physiological endogenous testosterone secretion while maintaining testicular volume and, potentially, spermatogenesis. In clinical trials conducted to date, enclomiphene demonstrated significant efficacy in the physiological restoration of testosterone levels in males with secondary hypogonadism. The compound also exhibited an unanticipated favorable effect on fasting plasma glucose; this result has been accompanied by rapidly accumulating evidence from other researchers for a bidirectional relationship between low serum testosterone and obesity/metabolic syndrome (syndrome X) in men. Short-term clinical safety data for enclomiphene have been satisfactory and equivalent to safety data for testosterone gels and placebo. Enclomiphene demonstrates promise in the management of secondary hypogonadism associated with obesity, metabolic syndrome and, possibly, infertility, and should undergo placebo-controlled, randomized clinical trials for these indications.

  2. New Member
    made2last's Avatar
    Stats
    5'9"   lbs.
    Join Date
    May 2014
    Posts
    193
    Rep Power
    67998
    Level
    16
    Lv. Percent
    80.64%

    Quote Originally Posted by Random987 View Post
    With all the talk about SARMS as being the wave of the future for TRT, it appears they are still looking at other options...

    Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men.
    Hill S, Arutchelvam V, Quinton R.

    Department of Clinical Pharmacology & Therapeutics, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.

    Enclomiphene (Androxal), in development by Repros Therapeutics Inc, is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes. Enclomiphene constitutes the trans-stereoisomer of clomiphene citrate, a drug that has been widely prescribed for several decades for the treatment of female ovulatory dysfunction. Because of the antagonistic effects of enclomiphene, the drug has the potential to increase serum testosterone levels in men with secondary hypogonadism by restoring physiological endogenous testosterone secretion while maintaining testicular volume and, potentially, spermatogenesis. In clinical trials conducted to date, enclomiphene demonstrated significant efficacy in the physiological restoration of testosterone levels in males with secondary hypogonadism. The compound also exhibited an unanticipated favorable effect on fasting plasma glucose; this result has been accompanied by rapidly accumulating evidence from other researchers for a bidirectional relationship between low serum testosterone and obesity/metabolic syndrome (syndrome X) in men. Short-term clinical safety data for enclomiphene have been satisfactory and equivalent to safety data for testosterone gels and placebo. Enclomiphene demonstrates promise in the management of secondary hypogonadism associated with obesity, metabolic syndrome and, possibly, infertility, and should undergo placebo-controlled, randomized clinical trials for these indications.
    still waiting for this
  3. Senior Member
    lexmuscle's Avatar
    Join Date
    Oct 2011
    Posts
    1,273
    Rep Power
    174561
    Level
    33
    Lv. Percent
    60.01%
    Achievements Activity ProPosting Pro

    Cool never heard of it until now
    •   
       

  4. Board Sponsor
    Royd The Noyd's Avatar
    Join Date
    May 2008
    Posts
    5,432
    Rep Power
    919167
    Level
    59
    Lv. Percent
    63.12%
    Achievements Activity ProActivity AuthorityPosting ProPosting Authority

    Repros just submitted the NDI earlier this month.
    ForeRunner Labs
    The Future of Human Performance
    Please LIKE FRL on Facebook

  5. New Member
    made2last's Avatar
    Stats
    5'9"   lbs.
    Join Date
    May 2014
    Posts
    193
    Rep Power
    67998
    Level
    16
    Lv. Percent
    80.64%

    Quote Originally Posted by Royd The Noyd View Post
    Repros just submitted the NDI earlier this month.
    What's the next step? How much longer? lol What's your thoughts on triptorelin?
  6. New Member
    LDubs's Avatar
    Stats
    6'2"  205 lbs.
    Join Date
    Jul 2014
    Posts
    144
    Rep Power
    119714
    Level
    22
    Lv. Percent
    19.87%

    Hmmm. Never heard of this before now. Looks interesting
  

  
 

Similar Forum Threads

  1. Replies: 4
    Last Post: 03-02-2015, 06:26 AM
Log in
Log in